IDDF2020-ABS-0201 Targeting hepatoma-intrinsic pparγ signaling overcomes immune checkpoint therapy resistance by inflaming the tumor microenvironment

BackgroundImmune-checkpoint blockade (ICB) therapies by antibodies against programmed death 1 (PD1)/PD1 ligand 1 (PD-L1) axis have revolutionized the treatment paradigm for cancer. Although subsets of people exhibit durable responses, ICB resistance has increasingly been observed, especially in hepa...

Ausführliche Beschreibung